A Phase 1/2 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed/ Refractory Acute Myeloid Leukemia.

CONCLUSIONS: These results are encouraging but a randomized trial is needed to address whether the addition of ixazomib to MEC improves outcome. Gene expression profiling also helped us identify predictors of response and potentially novel therapeutic targets.
PMID: 30992301 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - April 15, 2019 Category: Cancer & Oncology Authors: Advani A, Cooper BW, Visconte V, Elson P, Chan R, Carew JS, Wei W, Mukherjee S, Gerds A, Carraway H, Nazha A, Hamilton B, Sobecks RM, Caimi PF, Tomlinson B, Malek E, Little J, Miron A, Pink JJ, Maciejewski JP, Kalaycio ME, De Lima M, Unger A, Sekeres MA Tags: Clin Cancer Res Source Type: research